Literature DB >> 18414051

The level of oncogene H-Ras correlates with tumorigenicity and malignancy.

Beicheng Sun1, Yun Gao, Lei Deng, Guoqiang Li, Feng Cheng, Xuehao Wang.   

Abstract

Normal bovine adrenocortical cells and some human fibroblasts can be transformed by SV40T and H-Ras in a Ras-dependent manner. We recently reported that high levels of Ras derived from 5' LTR of retrovirrus can induce highly malignant and fast growing tumors, while lower levels of Ras derived from internal ribosome entry site (IRES) promotes slower tumor growth and loss of malignancy. Ras derived from CMV promoters resulted in much lower Ras levels and loss of tumor malignancy and growth. Further studies showed that the tumors formed in the presence of lower levels of Ras and dominant negative P53 (P53DD) had fewer apoptotic cells and grew faster than the tumors formed from cells with same level Ras and SV40T. Our studies suggest that low levels of Ras are insufficient to inhibit apoptosis induced by pRb inactivation. In contrast, high levels of Ras not only allow normal cells to exit senescence and form tumors, but also protect against pRb inhibition-induced cell apoptosis.

Entities:  

Mesh:

Year:  2008        PMID: 18414051     DOI: 10.4161/cc.7.7.5622

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  3 in total

1.  Regulation of a TGF-β1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells.

Authors:  J Wu; M Lu; Y Li; Y-K Shang; S-J Wang; Y Meng; Z Wang; Z-S Li; H Chen; Z-N Chen; H Bian
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

2.  MTH1 expression is required for effective transformation by oncogenic HRAS.

Authors:  Maria G Giribaldi; Anisleidys Munoz; Katherine Halvorsen; Asmita Patel; Priyamvada Rai
Journal:  Oncotarget       Date:  2015-05-10

3.  Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin.

Authors:  F A Scholl; P A Dumesic; D I Barragan; J Charron; P A Khavari
Journal:  Oncogene       Date:  2009-02-09       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.